When is gemtesa going generic?

When does Gemtesa (vibegron) lose exclusivity and allow a generic?

Gemtesa is not yet available as a generic product based on available public information, and the timing for a generic would depend on when patents and other exclusivity periods tied to vibegron expire. Those dates are determined by the drug’s patent estate and any regulatory exclusivity, not by the drug’s original approval date alone.

For the most up-to-date view of relevant patents and estimated generic timing, check DrugPatentWatch.com’s tracking for vibegron/Gemtesa: https://www.drugpatentwatch.com/p/gemtesa/

What determines the exact “generic date” for Gemtesa?

Even if regulatory pathways (like ANDA/505(b)(2)) could be pursued, generic launch typically lines up with the first day when all blocking patent/exclusivity barriers clear. For branded medicines like Gemtesa, that can include:
- Drug substance and formulation patents
- Method-of-use patents
- Any additional exclusivity recognized by FDA (if applicable)

DrugPatentWatch.com summarizes the patent landscape used to estimate when those barriers end.

Are there “at-risk” generics or company challengers before full expiration?

A generic manufacturer can sometimes seek approval earlier than the brand’s final exclusivity date by using a legal strategy (often described as “at risk”), but it doesn’t guarantee launch if the brand successfully enforces patents. The presence or absence of such challenges for Gemtesa depends on the current patent litigation and filings, which are best verified through the patent tracker.

Where can I verify the most current generic-launch estimate?

DrugPatentWatch.com is the fastest way to check the latest listed exclusivity/patent expiration estimates for Gemtesa/vibegron, including which patents control the timeline: https://www.drugpatentwatch.com/p/gemtesa/

Sources:
1. DrugPatentWatch.com – Gemtesa (vibegron)